PEGASUS is a support project financed by the 7th Framework Programme FP7, KBBE 2008 GA 226465, European Commission, DG Research.
- Unfortunately, your cookie settings do not allow social media buttons to be displayed. - check your settings
The general aim of PEGASUS is to provide policy with cons and
pros regarding GM animals, and derivative foods and pharmaceutical products. The
results will contribute to the FP7 KBBE by integrating existing social,
(including existing public perception) environmental and economic knowledge
regarding GM animals.
Despite considerable European innovations occurring in the area of GM animal technology, many of these current activities in the field of GM food animals take place outside the EU, in particular regions like the Far East, North America, and Australia-New Zealand. It can be envisaged that some of these animals still find their way into the European food supply chain through imports from overseas, in particular given that the EU is the world’s largest international trading block for food commodities.
Still, in Europe there is an ongoing discussion about GM crops, foods and pharmaceutical products derived from genetically modified (GM) animals which have not entered the European market yet. For discussion on societal issues, such as safety and ethics of foods and pharmaceutical products derived from cloned animals, well-balanced information is needed
Taking into account public perceptions, the competitiveness of EU animal production, and risk-benefit assessments linked with human and animal health, environmental impact, and sustainable production, the results of PEGASUS will provide European policy with pros and cons regarding GM animals and the foods and pharmaceuticals products derived from them.
The objective of PEGASUS is to provide cons and pros for future policy regarding GM animals, together with the foods and pharmaceutical products derived from them. The aim of PEGASUS is:
- To aid the EU’s policy assessment of the relevant research programmes and commercial application of these GM animals together with the foods and pharmaceutical products derived from them.
- To identify ethical concerns regarding their introduction, and societal barriers to commercialisation.
- To identify issues raised as part of the technology appraisal process.
These outcomes will contribute to and inform the EU’s current work to further development the Knowledge Based Bio Economy (KBBE) and contribute to obtainment of its strategic objectives.
To identify by literature and expert interviews the most
important current and future short-, medium-, and long–term technical
developments in the area of genetic modification, applied to animals
for food and pharmaceutics and the importance for the (future) competitiveness
of the European animal production.
- To provide insight into the economic dimensions (economic performance, chain
governance) of using GM animals in the food and pharmaceutical production
To produce a literature overview and an expert consultation of the
risks and benefits associated with GM animal products in the
food and pharmaceutical chain , from the point of view of the life
- To identify consumer perceptions associated with GM animals
and derived food and pharmaceutical products by integrating existing national
and European data.
- To collate the documented ethical concerns (positive as
negative) raised by stakeholder groups (breeders and farmers, scientists and
food- and pharmaceutical industry, NGO’s and policy makers) in different
European countries. A final multi-stakeholder group will be held in India.
Emerging ethical themes will be categorized and the relation to policy
development and governance practice will be identified.
- To identify policy gaps (national, (pan-) European, India
and USA) and recommend the policy options to be considered.
- To provide an integrated analysis of public concerns and
preferences for the strategic development and application of GM
animals, including the food and pharmaceutical products derived from them.
- To identify future European policy and research needs regarding GM animals for policy makers, end-users and researchers.
The interrelationship and the inputs of each Work Package into other Work Packages are schematically depicted in this figure:
|Deliverable 7.3.pdf||WP7||draft final report||04/09/2012|
|WP6 Final presentation.pdf||WP6||Final presentation||05/07/2012|
|WP5 Final presentation.pdf||WP5||Final presentation||05/07/2012|
|WP3 Final presentation.pdf||WP3||Final presentation||05/07/2012|
|WP2 and WP4 Final presentation.pdf||WP2||Final presentation WP2 and 4||05/07/2012|
|WP1 Final presentation.pdf||WP1||Final presentation||05/07/2012|
|Background on Pegasus during final meeting.pdf||background on Pegasus project||05/07/2012|
|Introduction to Pegasus during final meeting.pdf||Introduction on Pegasus project||05/07/2012|
|GMO governance.pdf||WP6||GMO Governance||14/03/2012|
|Pegasus_WP3_Deliverable_D 3.1.pdf||WP3||WP3 Deliverable||20/01/2012|
|PEGASUS_WP6Report_GM animals.pdf||WP6||WP6 Deliverable||25/11/2011|
|Polyclonals ABB 11.pdf||WP2||review Polyclonals||04/07/2011|
|PEGASUS(WP6)_GMO_Governance.pdf||WP6||Activity 6.1 report||14/06/2011|
|1002FABRE-TP News flash projectsforpdf.pdf||WP8||livestock projects FP7||14/02/2011|
|Define environmental risk assesment criteria for G||WP4||EFSA||10/08/2010|